Mersana Therapeutics MRSN 深 沪
已收盘 12-19 16:00:00 美东时间
29.05
-0.050
-0.17%
华盛通- 最 高29.39
- 今 开29.29
- 成交量 8.49万股
- 最 低 27.25
- 昨 收 29.10
- 总市值 28.18亿
- 52周最高 29.39
- 市盈率 静 --
- 换手率 0.09%
- 52周最低 0.26
- 委 比 0.00%
- 总股本 9699.13万
- 历史最高 29.39
- 量 比 1.26
- 振 幅 7.35%
- 历史最低 0.26
- 每 手 1
- 风险率 8.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Dow Dips Over 400 Points; JD.com Posts Upbeat Q3 Results
U.S. stocks traded lower midway through trading, with the Nasdaq Composite fall...
11-14 01:03
Mersana Therapeutics Earnings Preview
Mersana Therapeutics (NASDAQ:MRSN) is preparing to release its quarterly earnin...
11-14 00:02
Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout
Day One Biopharmaceuticals plans to acquire Mersana Therapeutics in a deal worth up to $285 million to expand its cancer drug portfolio.
11-13 23:15
Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting
Mersana Therapeutics announced interim Phase 1 data for Emi-Le, a B7-H4-targeted ADC, showing strong clinical activity in cancers like TNBC and ovarian cancer, with a 31% ORR in B7-H4 high tumors and a 44% ORR in patients with ≤4 prior therapies. The trial's safety profile remains favorable.
06-02 12:10
Citigroup Maintains Buy on Mersana Therapeutics, Lowers Price Target to $5
Citigroup analyst Ashiq Mubarack maintains Mersana Therapeutics (NASDAQ:MRSN) with a Buy and lowers the price target from $6 to $5.
2024-08-27 22:40
